AU2019396450B2 - Methods of treating schizophrenia and other neuropsychiatric disorders - Google Patents

Methods of treating schizophrenia and other neuropsychiatric disorders

Info

Publication number
AU2019396450B2
AU2019396450B2 AU2019396450A AU2019396450A AU2019396450B2 AU 2019396450 B2 AU2019396450 B2 AU 2019396450B2 AU 2019396450 A AU2019396450 A AU 2019396450A AU 2019396450 A AU2019396450 A AU 2019396450A AU 2019396450 B2 AU2019396450 B2 AU 2019396450B2
Authority
AU
Australia
Prior art keywords
scz
ctr
smad4
uptake
dox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019396450A
Other languages
English (en)
Other versions
AU2019396450A1 (en
Inventor
Steven A. Goldman
Zhengshan LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of AU2019396450A1 publication Critical patent/AU2019396450A1/en
Application granted granted Critical
Publication of AU2019396450B2 publication Critical patent/AU2019396450B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2019396450A 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders Active AU2019396450B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778145P 2018-12-11 2018-12-11
US62/778,145 2018-12-11
PCT/US2019/065742 WO2020123663A1 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
AU2019396450A1 AU2019396450A1 (en) 2021-06-24
AU2019396450B2 true AU2019396450B2 (en) 2025-08-28

Family

ID=69160318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019396450A Active AU2019396450B2 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Country Status (7)

Country Link
US (1) US20220025379A1 (cg-RX-API-DMAC7.html)
EP (1) EP3894556A1 (cg-RX-API-DMAC7.html)
JP (2) JP7518547B2 (cg-RX-API-DMAC7.html)
CN (2) CN113728103B (cg-RX-API-DMAC7.html)
AU (1) AU2019396450B2 (cg-RX-API-DMAC7.html)
CA (1) CA3122289A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020123663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
CN118924886A (zh) * 2023-03-16 2024-11-12 郑州大学 肿瘤共享新抗原表位肽或其编码核酸的新用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US6013787A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
EP2182063A3 (en) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
US7128264B2 (en) 2004-07-23 2006-10-31 Symbol Technologies, Inc: Electro-optical reader with improved performance in high intensity ambient light
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2315829B1 (en) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
WO2011062963A2 (en) 2009-11-17 2011-05-26 Vitro Diagnositics, Inc. Induced puripotent stem cells and related methods
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
EP2723861A4 (en) * 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
AU2012332269B2 (en) * 2011-11-04 2018-05-31 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US20180263226A1 (en) 2015-01-16 2018-09-20 The Board Of Regents Of The University Of Texas System Compositions and methods for creating pancreatic cancer animal model

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PING-TAO TSENG ET AL: "Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia : A Meta-analysis Study", MEDICINE., vol. 95, no. 4, January 2016, US, pages e2475, XP055674322, DOI: 10.1097/MD.0000000000002475 *
TAKAHIRO MUKAI ET AL: "Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region", FRONTIERS IN PHARMACOLOGY, vol. 9, 6 August 2018 (2018-08-06), pages 845, XP055674387, DOI: 10.3389/fphar.2018.00845 *
WANG PO-SHENG ET AL: "The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY,, vol. 29, no. 4, July 2014, 235 - 238, DOI: 10.1097/YIC.0000000000000027 *
ZHENGSHAN LIU: "The Contribution of Glial Molecular Pathology to Schizophrenia", PH. D. THESIS, 2017, Rochester, New York, USA, XP055672545, Retrieved from the Internet [retrieved on 20200302] *

Also Published As

Publication number Publication date
CA3122289A1 (en) 2020-06-18
CN113728103A (zh) 2021-11-30
JP7518547B2 (ja) 2024-07-18
CN113728103B (zh) 2025-02-28
US20220025379A1 (en) 2022-01-27
JP2024129091A (ja) 2024-09-26
WO2020123663A1 (en) 2020-06-18
JP2022511568A (ja) 2022-01-31
EP3894556A1 (en) 2021-10-20
CN119925614A (zh) 2025-05-06
AU2019396450A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US20220025379A1 (en) Methods of treating schizophrenia and other neuropsychiatric disorders
US20230287411A1 (en) Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases
US20220062378A1 (en) Methods of treating or inhibiting onset of huntington's disease
KR20190051020A (ko) 안 질환 치료용 안티센스 올리고뉴클레오타이드
JP2021520200A (ja) 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物
JP2024075673A (ja) 統合失調症及び他の神経精神障害の治療方法
CN104302768A (zh) 治疗β-联蛋白相关疾病的有机组合物
US20190111071A1 (en) Method for promoting muscle regeneration
EP4249589A1 (en) In vitro genetic disease model cell and method for producing the same
JP7834290B2 (ja) 医薬組成物
JP2025535055A (ja) Unc13aアンチセンスオリゴヌクレオチド及びその使用
EP4397766A1 (en) Pharmaceutical composition utilizing bornavirus vector
US20220186228A1 (en) Synthetic microrna mimics
US20260022377A1 (en) Polynucleotide compositions and methods for treatment of neurodegenerative diseases
HK40129245A (en) Unc13a antisense oligonucleotides and uses thereof
US20150104870A1 (en) Neuronal differentiation promoter
TW202108763A (zh) 用於治療ipf及pf-ild之病毒載體及核酸
Suh Differential Effect of DLX2 in Neural Precursors Derived from the Anterior and Hippocampal Subventricular zone
KR20190071930A (ko) 신경줄기세포 또는 신경전구세포에서 도파민 신경세포로의 분화방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)